CongressTop Stories Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen By Political Opinion - December 29, 2022 0 19 Share Facebook Twitter Pinterest WhatsApp The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”